



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

ANNOUNCEMENT OF 2008 ESTIMATED INTERIM RESULTS

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

Based on the preliminary management accounts prepared by the Group in accordance with HKFRSs, the net profit of the Group for the six months ended 30 June 2008 is expected to be at least 1.72 times of that for the six months ended 30 June 2007.

The financial information of the Group for the six months ended 30 June 2008 referred to in this announcement is preliminary, unaudited, and may be different from the interim financial information to be published. The Board confirmed that the disclosure of the financial information of the Group for the six months ended 30 June 2008 referred to in this announcement is made after due and careful enquiry.

The substantial increase in net profit for the first half of 2008 does not warrant a similar increase in net profit for the second half of 2008.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited.

The board of the directors (the "Board") of The United Laboratories International Holdings Limited (the "Company") announces the estimated interim results of the Company and its subsidiaries (the "Group") for the six months ended 30 June 2008 as follows:

(1) Estimated results for the six months ended 30 June 2008

Based on the preliminary management accounts prepared by the Group for the six months ended 30 June 2008 in accordance with Hong Kong Financial Reporting Standards ("HKFRSs"), the estimated net profit of the Group for the six months ended 30 June 2008 is expected to be at least 1.72 times of that for the six months ended 30 June 2007. Detailed financial information will be published in the forthcoming 2008 interim report of the Company.

The financial information of the Group for the six months ended 30 June 2008 referred to in this announcement is preliminary, unaudited, and may be different from the interim financial information to be published. The Board confirmed that the disclosure of the financial

information of the Group for the six months ended 30 June 2008 referred to in this announcement is made after due and careful enquiry.

The substantial increase in net profit for the first half of 2008 does not warrant a similar increase in net profit for the second half of 2008.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

(2) Results of the corresponding period in 2007

The net profit attributable to the equity holders of the Company for the six months ended 30 June 2007 was HK\$174.3 million.

The earnings per share of the Company for the six months ended 30 June 2007 was HK\$0.188.

The above financial figures were prepared in accordance with HKFRSs.

(3) Reason for increase in results

The increase in net profit for the six months ended 30 June 2008 was mainly attributable to the increase in the sales of intermediate products and finished products resulted from the increase in production capacity of the new production plant in Inner Mongolia.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Choy Kam Lok
Chairman

Hong Kong, 7 August 2008

As at the date of this announcement, the Board comprises Mr Choy Kam Lok, Ms Peng Wei and Mr Leung Wing Hon as executive directors; Ms Choy Siu Chit as non-executive director; and Messrs Heng Kwoo Seng, Huang Bao Guang and Song Ming as independent non-executive directors.